Atibuclimab not checked

Implicit Bioscience · IC14 · Anti-CD14

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
9 in total
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
Tested for
Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Main trialPhase 2
“Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days. The primary outcome is the day 4 oxygenation index assessed as a continuous measure.”In the company’s words, NCT06513949 on ClinicalTrials.gov
Other names
IC14 · Anti-CD14 · monoclonal antibody against CD14 · anti-CD14 monoclonal antibody

Other drugs for Acute Respiratory Distress Syndrome

All 23 drugs for Acute Respiratory Distress Syndrome

Coming up1

Changes4

Last 90 days

Trials9

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 1 Mar 2029 Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
Phase 2Withdrawn Jan 2020 IC14 in Adult Patients With Dengue Fever
Phase 2Withdrawn Jun 2020 A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome
Phase 2Withdrawn 12 Apr 2021 IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)
Phase 2Withdrawn 15 May 2023 IC14 for Treatment of Amyotrophic Lateral Sclerosis
Phase 1/2Completed 15 Aug 2025 IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy
Phase 1/2Completed 1 Aug 2026 Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI
Phase 1/2Completed 30 Aug 2026 IC14 for Treatment of Acute Decompensated Heart Failure
Phase 1Completed 18 Apr 2018 Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Atibuclimab

Following is part of Solo: you see every change to Atibuclimab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in